Merck Delays Acceleron Deal Amidst Continuing Stakeholder Criticism

Merck Delays Acceleron Deal Amidst Continuing Stakeholder Criticism

Source: 
BioSpace
snippet: 

One month after striking an $11.5 billion deal to acquire Acceleron Pharma, Merck temporarily withdraws its merger agreement to allow more time for review from the U.S. Federal Trade Commission and the U.S. Department of Justice.